ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 86 filers reported holding ONCOMED PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 1.20 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $394,000 | +16.9% | 42,733 | -2.3% | 0.00% | 0.0% |
| Q4 2016 | $337,000 | -34.4% | 43,733 | -2.7% | 0.00% | 0.0% |
| Q3 2016 | $514,000 | +13.7% | 44,933 | +22.3% | 0.00% | 0.0% |
| Q2 2016 | $452,000 | +24.9% | 36,733 | +2.6% | 0.00% | 0.0% |
| Q1 2016 | $362,000 | -48.9% | 35,807 | +14.1% | 0.00% | -50.0% |
| Q4 2015 | $708,000 | +38.6% | 31,389 | +1.9% | 0.00% | +100.0% |
| Q3 2015 | $511,000 | -26.5% | 30,789 | -0.3% | 0.00% | -50.0% |
| Q2 2015 | $695,000 | +17.0% | 30,889 | +34.1% | 0.00% | +100.0% |
| Q1 2015 | $594,000 | +16.9% | 23,032 | -1.3% | 0.00% | 0.0% |
| Q4 2014 | $508,000 | +15.5% | 23,332 | +0.4% | 0.00% | 0.0% |
| Q3 2014 | $440,000 | -18.2% | 23,232 | +0.6% | 0.00% | 0.0% |
| Q2 2014 | $538,000 | +88.1% | 23,100 | +171.8% | 0.00% | 0.0% |
| Q1 2014 | $286,000 | +13.9% | 8,500 | 0.0% | 0.00% | 0.0% |
| Q4 2013 | $251,000 | +141.3% | 8,500 | +25.0% | 0.00% | – |
| Q3 2013 | $104,000 | – | 6,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,042,989 | $8,571,000 | 0.75% |
| NEXTHERA CAPITAL LP | 634,715 | $1,346,000 | 0.26% |
| Endurant Capital Management LP | 219,114 | $465,000 | 0.21% |
| Birchview Capital, LP | 118,689 | $252,000 | 0.16% |
| Perceptive Advisors | 2,620,897 | $5,556,000 | 0.15% |
| Alambic Investment Management, L.P. | 53,972 | $114,000 | 0.09% |
| Sofinnova Investments, Inc. | 395,744 | $839,000 | 0.08% |
| Kazazian Asset Management, LLC | 31,475 | $67,000 | 0.06% |
| Broadfin Capital, LLC | 200,000 | $424,000 | 0.06% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 96,639 | $205,000 | 0.02% |